



JUL 8 2002

Robin Weiner
Vice President, Clinical and Regulatory Affairs
Quidel Corporation
10165 McKellar Court
San Diego, California 92121

We have reviewed your information notifying CDRH of a trade name change.

Regulations codified at 42 CFR 493.15 et seq., implementing the Clinical Laboratory Improvement Amendments of 1988, require the Secretary to provide for the categorization of specific clinical laboratory test systems by the level of complexity. Based upon these regulations, the following commercially marketed test system or assay for the analyte is categorized below:

Test System: Quidel QuickVue® In-Line Strep A

Analyte: Streptococcus, Group A

RE: k934484/a10

Complexity: Waived

This complexity categorization is effective as of the date of this notification. This categorization will be reported on FDA's home page <http://www.fda.gov/cdrh/clia>. This categorization information may be provided to the user of the commercially marketed test system or assay as specified for the analytes indicated. This categorization will also be announced in a Federal Register Notice, which will provide opportunity for comment on the decision. FDA reserves the right to reevaluate and recategorize this test based upon the comments received in response to the Federal Register Notice. For questions regarding FDA's categorization procedure, contact Clara A. Sliva, Acting CLIA Coordinator, at (301) 827-0496 or email <http://www.CLIA@CDRH.FDA.GOV>.

Sincerely yours,

Steven I. Gutman, MD, MBA
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological
Health